Ondine Biomedical Inc.
LSE : OBP

Ondine Biomedical Inc.

March 14, 2011 12:29 ET

Ondine Biomedical Announces Share Issuance

FOR:  ONDINE BIOMEDICAL INC.

TSX, AIM SYMBOL:  OBP

March 14, 2011

Ondine Biomedical Announces Share Issuance

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 14, 2011) - Ondine Biomedical Inc. ("Ondine" or the
"Company") (TSX:OBP)(AIM:OBP) today announced it has issued 88,201 common shares at a weighted average
price of $0.73 per share to an arm's length supplier as consideration for and in settlement of amounts
owing in connection with product purchases. The shares are subject to a regulatory hold period in
Canada which expires on July 12, 2011. Application has been made for these shares to be admitted to
trading on AIM and dealings are expected to commence on March 17, 2011.

About Ondine Biomedical Inc.

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial,
fungal and viral infections. The Company is focused on developing leading edge products utilizing its
patented light-activated technology, primarily for the healthcare-associated infection (HAI) market.
Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and
spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a
research and development laboratory in Bothell, Washington, USA. For additional information, please
visit the Company's website at: www.ondinebio.com.


-30-

FOR FURTHER INFORMATION PLEASE CONTACT:

Ondine Biomedical Inc.
Carolyn Cross
Chairman and CEO
ccross@ondinebio.com

OR

Canaccord Genuity Limited
Mark Williams/Bhavesh Patel
Nominated Adviser
+4420 7050 6500

Contact Information

  • Ondine Biomedical Inc.